论文部分内容阅读
目的：糖尿病是最常见的内分泌代谢疾病之一，了解口服降糖药在上海市医院的应用情况，作出客观的评估，供生产、营销、使用等部门参考。方法：调查上海市４６ 家医院５ 年来（１９９４ 年～１９９８ 年） 经营金额、主要品种数量、ＤＤＤｓ 以及临床的评价。结果：５ 年来，口服降糖药经营金额明显高于药品经营总金额增长比例（４－３３ ∶１－５４） 。金额数排序为格列齐特、阿卡波糖和二甲双胍；用量和ＤＤＤｓ 排序为格列齐特、格列吡嗪和二甲双胍。笔者深入临床调查了常用品种的应用情况，提出了合理用药建议。结论：口服降糖药是当前国内一类具有发展前途的常用药物，提倡合理应用。
Objective: Diabetes mellitus is one of the most common endocrine and metabolic diseases. To understand the application of oral hypoglycemic agents in Shanghai hospitals, make an objective assessment for the production, marketing, use and other departments. Methods: The operating amount, main varieties, DDDs and clinical evaluation of 46 hospitals in Shanghai during the past 5 years (from 1994 to 1998) were investigated. Results: In the past five years, the operating cost of oral hypoglycemic agents was significantly higher than that of the total amount of drug business operations (4-33: 1-54). The amounts were ranked as gliclazide, acarbose and metformin; dosage and DDDs were ranked as gliclazide, glipizide and metformin. The author in-depth clinical investigation of the application of commonly used varieties, put forward a reasonable drug recommendations. Conclusion: Oral hypoglycemic agents are currently a kind of commonly used drugs with promising development in our country, and promote rational application.